Can PET study by using [11C] PK11195 radioligand acting to S1P receptors reduce the microglia-tissue activity in the brain of MS patients?

Trial Profile

Can PET study by using [11C] PK11195 radioligand acting to S1P receptors reduce the microglia-tissue activity in the brain of MS patients?

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2016 Status changed from recruiting to completed.
    • 17 Sep 2016 Primary endpoint has not been met. (Microglia activity is measured by PET imaging and 11C-PK11195 radiogland)
    • 17 Sep 2016 Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top